Key Insights

Highlights

Success Rate

50% trial completion

Treatment Research

7 treatments under study, led by Immunosuppression Taper

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 55/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

50.0%

-36.6% vs benchmark

Late-Stage Pipeline

75%

3 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed with results

Key Signals

1 with results50% success

Data Visualizations

Phase Distribution

4Total
Not Applicable (1)
Phase 4 (3)

Trial Status

Completed1
Enrolling By Invitation1
Unknown1
Terminated1

Trial Success Rate

50.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT04786067Phase 4CompletedPrimary

Use of DNA Testing to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression

NCT01424345Phase 4TerminatedPrimary

The Role of ImmuKnow® in the Management of Immunosuppressants in the Renal Transplant Patient

NCT06336863Not ApplicableEnrolling By InvitationPrimary

Use of DNA Testing and Gene Expression Profiling to Help Transition Kidney Transplant Recipients to Belatacept-only Immunosuppression

NCT06114953Phase 4UnknownPrimary

Comparative Efficacy of Mizoribine With Mycophenolate Mofetil for Living Related Kidney Transplantation Recipients

Showing all 4 trials

Research Network

Common Treatments

  • Immunosuppression Taper1
  • Mizoribine1
  • Adjustment Of Immunosuppressant Dosages1
  • Adjustment Of The Dosages Of Immunosuppressants1
  • Belatacept1

Active Sponsors

  • University of Texas Southwestern Medical Center2
  • CareDx1
  • Lee's Pharmaceutical Limited1
  • CAMC Health System1

Top Investigators

Activity Timeline